Systematic literature review of quality‐of‐life questionnaires in Waldenström macroglobulinaemia—need for a disease‐specific tool

[...]we conducted a literature review of the currently used QoL tools in WM. Of the 10 studies identified, 14 non-mutually exclusive questionnaires were applied, often in combination, to report QoL: European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire-Cancer30...

Full description

Saved in:
Bibliographic Details
Published in:EJHaem 2023-05, Vol.4 (2), p.555-558
Main Authors: Bristogiannis, Sotirios, Khwaja, Jahanzaib, Lwin, Yadanar, Uppal, Encarl, D'Sa, Shirley, Kyriakou, Charalampia
Format: Article
Language:English
Subjects:
Anemia
Anxiety
Cancer
Cancer therapies
Chronic illnesses
Clinical trials
Cognitive ability
Correspondence
Dyspnea
Fatigue
Literature reviews
Lymphoma
Mental depression
Mental health
Neurotoxicity
Non-Hodgkin's lymphoma
Patients
Peripheral neuropathy
Quality of life
Quantitative psychology
Questionnaires
Rituximab
Stress
Validity
Waldenström's macroglobulinaemia
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]we conducted a literature review of the currently used QoL tools in WM. Of the 10 studies identified, 14 non-mutually exclusive questionnaires were applied, often in combination, to report QoL: European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire-Cancer30 (EORTC QLQ-C30), five level EuroQol five-dimensional questionnaire (EQ-5D-5L), Functional Assessment of Cancer Therapy-General (FACT-G), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), FACT-Anaemia (FACT-An), FACT-Gynecologic Oncology Group-Neurotoxicity (FACT-GOG NTx), FACT-Lymphoma (FACT-Lym), 36-Item Short Form Survey (SF-36), Hospital Anxiety and Depression Scale (HADS), Depression Anxiety Stress Scales-21 (DASS-21), Quality of Life in Cancer Survivors (QLACS), Impact of Event Scale-6 (IES-6), Fatigue Severity Scale (FSS) and Impact on Participation and Autonomy questionnaire (IPA). [...]the phase III CHRONOS-3 trial failed to show any QoL benefit for patients with non-Hodgkin lymphoma including 38 patients with WM that received copanlisib in addition to rituximab versus placebo [ 10].
ISSN:2688-6146
2688-6146
DOI:10.1002/jha2.668